USD 5.88
(-2.0%)
Year | Inventory | Inventory Growth |
---|---|---|
2023 | -2.44 Million USD | 0.0% |
2022 | - USD | -100.0% |
2021 | 1.00 USD | 0.0% |
2020 | - USD | 0.0% |
2019 | - USD | -100.0% |
2018 | 1.00 USD | 0.0% |
2017 | - USD | 0.0% |
2016 | - USD | -100.0% |
2015 | 1.00 USD | 0.0% |
2014 | - USD | -100.0% |
2013 | 1.00 USD | -100.0% |
2012 | 194 Thousand USD | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2024 Q2 | - USD | 0.0% |
2024 Q1 | - USD | 0.0% |
2023 Q3 | - USD | -100.0% |
2023 Q1 | - USD | 0.0% |
2023 FY | - USD | 0.0% |
2023 Q2 | 1.00 USD | 0.0% |
2023 Q4 | - USD | 0.0% |
2022 Q1 | - USD | -100.0% |
2022 FY | - USD | -100.0% |
2022 Q4 | - USD | -100.0% |
2022 Q3 | 1.00 USD | 0.0% |
2022 Q2 | - USD | 0.0% |
2021 FY | 1.00 USD | 0.0% |
2021 Q1 | - USD | 0.0% |
2021 Q3 | - USD | 0.0% |
2021 Q4 | 1.00 USD | 0.0% |
2021 Q2 | - USD | 0.0% |
2020 Q1 | - USD | 0.0% |
2020 FY | - USD | 0.0% |
2020 Q2 | - USD | 0.0% |
2020 Q3 | 1.00 USD | 0.0% |
2020 Q4 | - USD | -100.0% |
2019 Q4 | - USD | 0.0% |
2019 FY | - USD | -100.0% |
2019 Q3 | - USD | 0.0% |
2019 Q2 | - USD | 0.0% |
2019 Q1 | - USD | -100.0% |
2018 Q2 | 1.00 USD | 0.0% |
2018 FY | 1.00 USD | 0.0% |
2018 Q1 | - USD | 0.0% |
2018 Q4 | 1.00 USD | 0.0% |
2018 Q3 | 1.00 USD | 0.0% |
2017 Q1 | 1.00 USD | 0.0% |
2017 FY | - USD | 0.0% |
2017 Q3 | - USD | -100.0% |
2017 Q4 | - USD | 0.0% |
2017 Q2 | 1.00 USD | 0.0% |
2016 Q2 | - USD | 0.0% |
2016 Q1 | - USD | -100.0% |
2016 FY | - USD | -100.0% |
2016 Q4 | - USD | 0.0% |
2016 Q3 | - USD | 0.0% |
2015 Q1 | -1.00 USD | 0.0% |
2015 FY | 1.00 USD | 0.0% |
2015 Q4 | 1.00 USD | 0.0% |
2015 Q3 | - USD | -100.0% |
2015 Q2 | 1.00 USD | 200.0% |
2014 Q1 | - USD | -100.0% |
2014 Q2 | - USD | 0.0% |
2014 Q3 | 1.00 USD | 3435973836900.0% |
2014 FY | - USD | -100.0% |
2014 Q4 | - USD | -100.0% |
2013 Q2 | - USD | -100.0% |
2013 Q4 | 1.00 USD | 0.0% |
2013 Q1 | 150 Thousand USD | -22.68% |
2013 Q3 | - USD | 0.0% |
2013 FY | 1.00 USD | -100.0% |
2012 FY | 194 Thousand USD | 0.0% |
2012 Q4 | 194 Thousand USD | 0.0% |
Name | Inventory | Inventory Difference |
---|---|---|
Editas Medicine, Inc. | - USD | Infinity% |
Dynavax Technologies Corporation | 53.29 Million USD | 104.586% |
Supernus Pharmaceuticals, Inc. | 77.4 Million USD | 103.157% |
Perrigo Company plc | 1.14 Billion USD | 100.214% |
Illumina, Inc. | 587 Million USD | 100.416% |
Thermo Fisher Scientific Inc. | 5.08 Billion USD | 100.048% |
Iovance Biotherapeutics, Inc. | 10.37 Million USD | 123.563% |
Walgreens Boots Alliance, Inc. | 8.32 Billion USD | 100.029% |
IQVIA Holdings Inc. | - USD | Infinity% |
Heron Therapeutics, Inc. | 42.11 Million USD | 105.804% |
Regeneron Pharmaceuticals, Inc. | 2.58 Billion USD | 100.095% |
Unity Biotechnology, Inc. | - USD | Infinity% |
Waters Corporation | 516.23 Million USD | 100.473% |
Biogen Inc. | 2.52 Billion USD | 100.097% |
Sangamo Therapeutics, Inc. | - USD | Infinity% |
Evolus, Inc. | 10.99 Million USD | 122.222% |
Adicet Bio, Inc. | - USD | Infinity% |
Cara Therapeutics, Inc. | 2.82 Million USD | 186.636% |
bluebird bio, Inc. | 22.91 Million USD | 110.664% |
Esperion Therapeutics, Inc. | 65.62 Million USD | 103.724% |
FibroGen, Inc. | 41.56 Million USD | 105.88% |
Agilent Technologies, Inc. | 1.03 Billion USD | 100.237% |
Corbus Pharmaceuticals Holdings, Inc. | - USD | Infinity% |
Homology Medicines, Inc. | - USD | Infinity% |
Geron Corporation | - USD | Infinity% |
Alnylam Pharmaceuticals, Inc. | 89.14 Million USD | 102.742% |
Amicus Therapeutics, Inc. | 59.69 Million USD | 104.094% |
Myriad Genetics, Inc. | 20.1 Million USD | 112.159% |
Viking Therapeutics, Inc. | - USD | Infinity% |
Intellia Therapeutics, Inc. | - USD | Infinity% |
Zoetis Inc. | 2.56 Billion USD | 100.095% |
Mettler-Toledo International Inc. | 385.86 Million USD | 100.633% |
BioMarin Pharmaceutical Inc. | 1.1 Billion USD | 100.221% |
Vertex Pharmaceuticals Incorporated | 738.8 Million USD | 100.331% |
Kala Pharmaceuticals, Inc. | - USD | Infinity% |
Ionis Pharmaceuticals, Inc. | 28.42 Million USD | 108.598% |
Atara Biotherapeutics, Inc. | 9.7 Million USD | 125.18% |
Verastem, Inc. | - USD | Infinity% |
Nektar Therapeutics | 16.1 Million USD | 115.179% |
Axsome Therapeutics, Inc. | 15.13 Million USD | 116.148% |
Aclaris Therapeutics, Inc. | - USD | Infinity% |
Sarepta Therapeutics, Inc. | 322.85 Million USD | 100.757% |
OPKO Health, Inc. | 65.69 Million USD | 103.72% |
Exelixis, Inc. | 17.32 Million USD | 114.108% |
Neurocrine Biosciences, Inc. | 38.3 Million USD | 106.381% |
Corcept Therapeutics Incorporated | 7.73 Million USD | 131.617% |
Anavex Life Sciences Corp. | - USD | Infinity% |
uniQure N.V. | 12.02 Million USD | 120.326% |
Imunon, Inc. | - USD | Infinity% |
Blueprint Medicines Corporation | 21.22 Million USD | 111.516% |
Insmed Incorporated | 83.24 Million USD | 102.936% |
Halozyme Therapeutics, Inc. | 127.6 Million USD | 101.915% |
Agios Pharmaceuticals, Inc. | 19.07 Million USD | 112.812% |
TG Therapeutics, Inc. | 39.82 Million USD | 106.137% |
Incyte Corporation | 62.97 Million USD | 103.881% |
Emergent BioSolutions Inc. | 328.9 Million USD | 100.743% |